Lanthio Pharma licenses lanthionine-stabilized Angiotensin agonistic peptide drug to Tarix Pharmaceuticals
Lanthionine-stabilized Angiotensin-(1-7) is being developed for the treatment of acute lung injury and related indications with high unmet medical need. It is an agonistic peptide that was discovered by Lanthio Pharma, using its proprietary LanthioPep® technology. The compound is stable and resistant to angiotensin-converting enzyme. Additionally, it has high specificity for the MAS receptor and shows increased intrinsic activity compared to wild-type Angiotensin-(1-7).
Bart Wuurman, CEO of Lanthio Pharma commented; This deal with Tarix presents an early revenue opportunity and further validates the exciting potential of our technology to discover next generation peptide therapeutics that are more stable and more potent than classical peptides and hence have the characteristics that are required for successful innovative therapeutics.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.